Company Filing History:
Years Active: 2025
Title: Bo Chen - Innovator in RNAi Technology
Introduction
Bo Chen is a prominent inventor based in Scarsdale, NY (US). He has made significant contributions to the field of RNA interference (RNAi) technology, particularly in the development of agents that inhibit the expression of HIF-2 alpha. His work has implications for treating various diseases, including clear cell renal cell carcinoma (ccRCC).
Latest Patents
Bo Chen holds a patent for "RNAi agents for inhibiting expression of HIF-2 alpha, compositions thereof, and methods of use." This patent describes RNAi agents, specifically double-stranded RNAi agents, that can effectively inhibit the HIF-2 alpha (EPAS1) gene expression. The patent also details pharmaceutical compositions that incorporate these RNAi agents and outlines methods for their use. The agents can be linked to targeting ligands and pharmacokinetic enhancers to improve delivery to cells and tissues, particularly in ccRCC cells and tumors.
Career Highlights
Bo Chen is currently associated with Arrowhead Pharmaceuticals, Inc., where he continues to advance his research in RNAi technology. His innovative work has positioned him as a key figure in the development of therapeutic solutions for complex diseases.
Collaborations
Bo Chen collaborates with notable colleagues, including Zhen Li and Dongxu Shu, who contribute to the research and development efforts at Arrowhead Pharmaceuticals.
Conclusion
Bo Chen's contributions to RNAi technology and his innovative patent work highlight his role as a leading inventor in the field. His research has the potential to significantly impact the treatment of diseases like ccRCC.